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Available online 19 March 2016Background: Epigenetic modiﬁcations of the genome, such as DNA methylation and histone modiﬁcations, have
been reported to play a role in processes underlying cardiovascular disease (CVD), including atherosclerosis, in-
ﬂammation, hypertension and diabetes.
Methods: Eleven databases were searched for studies investigating the association between epigenetic marks
(either global, site-speciﬁc or genome-wide methylation of DNA and histone modiﬁcations) and CVD.
Results: Of the 3459 searched references, 31 studies met our inclusion criteria (26 cross-sectional studies and 5
prospective studies). Overall, 12,648 individuals were included, with total of 4037 CVD events. The global DNA
methylation assessed at long-interspersed nuclear element (LINE-1) was inversely associated with CVD, inde-
pendent of established cardiovascular risk factors. Conversely, a higher degree of global DNA methylation mea-
sured at Alu repeats or by the LUMA method was associated with the presence of CVD. The studies reported
epigenetic regulation of 34 metabolic genes (involved in fetal growth, glucose and lipid metabolism, inﬂamma-
tion, atherosclerosis and oxidative stress) in blood cells to be relatedwith CVD. Among them, 5 loci were validat-
ed and methylation at F2RL3 was reported in two large prospective studies to predict cardiovascular disease
beyond the traditional risk factors.
Conclusions: Current evidence supports an association between genomic DNA methylation and CVD. However,
this review highlights important gaps in the existing evidences including lack of large-scale epigenetic investiga-
tions, needed to reliably identify genomic loci where DNA methylation is related to risk of CVD.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
Epigenetic
DNA methylation
Histone modiﬁcations
LINE-1
Cardiovascular disease1. Introduction
There is a worldwide epidemic of cardiovascular disease (CVD) caus-
ing one-third of all deaths worldwide and counting for trillions of dollars
of health care expenditure [1,2]. Thisﬁgurewill surely increase in bothde-
veloping and developed countries as risk factors for the disease, such as
dyslipidemia, hypertension, obesity and diabetes continue to increase [2].
Current scientiﬁc knowledge does not completely explain the com-
plex pathophysiology underlying CVD and therefore a search for other
pathways is constantly being conducted. Epigenetic modiﬁcations ofgy, Erasmus University Medical
2040, 3000 CA Rotterdam, the
eliability and freedom from bias
land Ltd. This is an open access articlthe genome might constitute an additional pathway leading to CVD
[3]. Epigenetics refers to various dynamic features that modify the
genome's functionality under exogenous inﬂuence and also provide a
molecular substrate that allows for the stable propagation of gene ex-
pression states from one generation of cells to the next [4]. DNA meth-
ylation and histone modiﬁcations are the best understood of the
epigenetic mechanisms thus far [4], and have been suggested to regu-
late gene expression and affect CVD risk factors including atherosclero-
sis, inﬂammation, hypertension and diabetes [5–7]. Unlike mutations
and other genetic abnormalities, epigenetic modiﬁcations are dynamic
and could be modiﬁed by lifestyle and perhaps other therapeutic ap-
proaches [8,9]. Therefore, it has been suggested that these epigenetic
mechanisms can be important regulatory key players not only in under-
standing CVD's pathophysiology but also in both its diagnosis and treat-
ment [10]. To date, however, little work has been done to systematically
appraise the current evidence for the role of DNA methylation and his-
tone modiﬁcations on the risk of CVD.e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Flowchart of studies investigating epigenetic marks in relation to cardiovascular
disease.
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available evidences in humans to quantify the association of DNAmeth-
ylation and histone modiﬁcations with cardiovascular outcomes.
2. Material and methods
2.1. Literature search
This reviewwas conducted using a predeﬁned protocol and in accor-
dance with the PRISMA [11] and MOOSE [12] guidelines (eAppendix 1
and 2). Eleven bibliographic databases (Embase.com, Medline (Ovid),
Web-of-Science, Scopus, PubMed, Cinahl (EBSCOhost), Cochrane
Central, ProQuest, Lilacs, Scielo and Google Scholar) were searched
until May 27th 2015 (date last searched) without any language
restrictions, with the help of an experienced medical information spe-
cialist. The search strategy combined terms related to exposure
(e.g., epigenetics, DNA methylation, histone, and CpG) and outcomes
(e.g., cardiovascular disease, coronary disease, heart disease, cerebro-
vascular disease, myocardial infarction, stroke, ischemia, and carotid ar-
tery disease). In databases where a thesaurus was available (Embase,
Medline and Cinahl) articles were searched by thesaurus terms and by
title and/or abstract, and in other databases only by title and/or abstract.
We restricted the search to studies on humans. The full search strategies
of all databases are provided in eAppendix 3. After eliminating duplica-
tions, in total, we identiﬁed 3459 potentially relevant citations.
2.2. Study selection and inclusion criteria
Studies to be included either described an association between epi-
genetic marks (global, site speciﬁc or genome-wide methylation of
DNA or histone modiﬁcations) and cardiovascular outcomes deﬁned
as fatal or non-fatal coronary heart disease (CHD) and stroke. CHD
events included myocardial infarction, coronary artery bypass graft, is-
chemic heart disease or sudden cardiac death if caused by myocardial
infarction and CHD deaths. Stroke included both hemorrhagic and is-
chemic cerebrovascular events. Two independent reviewers, screened
the retrieved titles and abstracts and selected eligible studies. In case
of disagreement, decision was made through consensus or consultation
with a third independent reviewer. Full texts were retrieved for studies
that satisﬁed all selection criteria.
2.3. Data extraction
A predesigned data collection form was prepared to extract the rel-
evant information from the selected studies, including study design,
study population, location, age range, duration of follow up (for longitu-
dinal studies), and degree of adjustment. The degree of adjustment was
deﬁned as ‘+’ when the measures of association were adjusted for age
and non-established cardiovascular risk factors (e.g., education, income,
and ethnicity) and “++” when further adjustment was done for
established vascular risk factors and potential mediators (e.g., smoking
status, body mass index, lipids, and hypertension), tissue sample and
method used to assess epigenetic marks, for type and numbers
of cardiovascular outcomes and reported measures of associations
(e.g., correlation analysis, odds ratio, and relative risks).
2.4. Assessing the risk of bias
Bias within each individual study was evaluated using the validated
Newcastle–Ottawa Scale, a semi-quantitative scale designed to evaluate
the quality of nonrandomized studies [13]. Study quality was judged on
the selection criteria of participants, comparability of cases and controls,
and exposure and outcome assessment. Studies that received a score of
nine starswere judged to be at low risk of bias; studies that scored seven
or eight stars were considered to be at medium risk; those that scored
six or less were considered to be at high risk of bias.2.5. Outcome assessment and statistical methods
For each study, we deﬁned whether an association was reported,
and when applicable, direction effect sizes were reported. Heterogene-
ity permitting, we sought to pool the results using a random effects
meta-analysismodel. If pooled, results were expressed as the pooled es-
timate and the corresponding 95% conﬁdence intervals.
3. Results
In total, after deduplication, we identiﬁed 3459 potentially relevant
citations (Fig. 1). Based on the title and abstracts, full texts of 35 articles
were selected for detailed evaluation. Of those, 31 articles met
our eligibility criteria and were therefore included in the analysis
(Supplementary Tables S1–S2).
3.1. Summary of included studies
Overall, 12,648 individuals were included within the systematic re-
view,with a total of 4037 CVDoutcomes (3599 prevalent CVDoutcomes
and 439 incident CVD events) (Supplementary Tables S1–S2). Of the 31
studies included, 6 studies assessed the global DNA-methylation (4 case
control studies and 2 prospective studies), 20 studies assessed the DNA
methylation in speciﬁc candidate genes (17 cross-sectional studies and
3 longitudinal studies), 3 studies (all case control studies) used genome-
wide approaches, one study assessed histone modiﬁcations and one
study (case–control) examined both DNA methylation and histone
modiﬁcations in speciﬁc candidate genes in relation to CVD (Tables 1,
2 and Supplementary Tables S1–S2). Seven studies included partici-
pants fromChina, 4 studies from India and the rest included participants
from Canada, Germany, Italy, Spain, Scotland, Sweden, Romania, Iran
and the USA (Supplementary Tables S1–S2). All available studies were
cross-sectional, case control or prospective cohorts in design and were
judged as low or medium-quality studies, with only one study to be
judged as a high quality (Supplementary Tables S1–S2).
3.2. Global DNA methylation and cardiovascular disease
Global methylation refers to the overall level of methylcytosine in
the genome, expressed as percentage of total cytosine. A large portion
of methylation sites within the genome are found in repeat sequences
and transposable elements, such as Alu and long-interspersed nuclear
element (LINE-1) and correlate with total genomicmethylation content
Table 1
Global DNA methylation and cardiovascular disease.a
CVD outcome Tissue type Population Association, reference Comment
LINE-1 methylation
CHD, n = 344 PBL M and F,
n = 1122
Inverse association [20] LINE-1 methylation level was inversely associated
with the risk of CHD (relative to the subjects in the
fourth quartile of LINE-1 methylation ORs for CHD
were 0.9 (95% CI, 0.6–1.4), 1.9 (95% CI, 1.3–2.9), and
2.3 (95% CI, 1.6–3.5) for the subjects with
methylation in the third, second and ﬁrst quartile;
Ptrend b 0.001). The association tended to be
stronger among subjects with higher levels of
homocysteine (Pinteraction = 0.04) and those with
diagnosis of hypertension (Pinteraction = 0.01)
Ischemic stroke, n = 280) PB M and F,
n = 560
Inverse association in men;
no association in women [21]
In men, a decrease of 1% methylation level in men
was associated with an increased risk of stroke
(OR = 1.2; 95% CIs: 1.1–1.32).
-Non-fatal IHD (prevalent, n = 212, incident, n = 36)
-Non-fatal stroke (prevalent, n = 51; incident, n = 8)
-IHD mortality (n = 35)
-Stroke mortality (n = 10)
-Combined IHD and Stroke
WB M, n = 712 Inverse association [22] The associations were signiﬁcant in both
cross-sectional (combined incident non-fatal IHD
and stroke: 1st quartile vs. 4th quartile: OR = 2.2
95% CI = 1.2–3.9) and prospective analysis
(combined incident non-fatal IHD and stroke:
(bmedian vs. Nmedian: HR= 4.1, 95% CI= 1.9–8.7);
combined incident fatal IHD and stroke: (bmedian vs.
Nmedian: OR= 2.9, 95% CI = 1.3–6.2))
ALU
MI and/or stroke, n = 14 PBL M and F,
n = 286
Positive association [23] Subject with a MI and/or stroke at baseline showed a
signiﬁcantly higher mean of combined methylation
in ALU and SAT 2 repetitive elements (geometric
mean= 201 and 95% CI= 145–180, p=0.045). This
association was prominent inmen (p=0.02) but not
in women (p= 0.66).
HpaII/MspI ratio
CAD, n = 137 PBLb M and F,
n = 287
Positive association [24] Global DNA methylation was positively associated
with CAD (p= 0.02). The results differ by the levels
of plasma homocysteine.
CVD-mortality, n = 13 PBL M and F,
n = 56
Positive association [25] Global DNA hypermethylation (HpaII/MspI
ratio bmedian) was associated with increases risk
of CVD mortality (HR = 13.9, 95% CIs: 1.8–109.3.)
CAD, coronary artery disease; CHD, coronary heart disease; CI, conﬁdence interval; CVD, cardiovascular disease; F, female; IHD, ischemic heart disease;M,male;MI, myocardial infarction;
n, number; OR, odds ratio; PB, peripheral blood; PBL, peripheral blood leukocytes.
a Signiﬁcant inverse association with IHD and IHD and stroke combined but not with stroke.
b Levels of methylations estimated in terms of [3H] dCTP following MspI and HpaII.
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rogate for the overall methylation of the genome [17,18]. Other
methods (e.g., Luminometric Methylation Assay, LUMA and the [3H]-
methyl acceptance basedmethod) to asses global genomicDNAmethyl-
ation are primarily based on thedigestion of genomicDNAby restriction
enzymes HpaII and MspI [19].
All six studies that examined global DNA methylation and risk of
CVD used blood samples to assess DNA methylation (Table 1). Three
studies used LINE-1 methylation [20–22], one study used Alu methyla-
tion [23] and two studies used the LUMA method and the [3H]-methyl
acceptance based method to estimate the global genomic methylation
[24,25]. Four studieswere case control [20,21,23,24], one studywaspro-
spective [25] and one study used both cross-sectional and longitudinal
designs [22]. Five studies [20–22,24,25] adjusted for established CVD
risk factors whereas one study [23] did not (Supplementary Table S1).
3.2.1. LINE-1 methylation and cardiovascular disease
One cross-sectional study showed that lower levels of LINE-1 meth-
ylation were associated with the presence of CHD in both men and
women (comparing 1st quartile vs. 4th quartile: odds ratio (OR) =
2.3, 95% conﬁdence interval (CI)= 1.6–3.5), and this association tended
to be stronger among subjects with higher levels of homocysteine and
among hypertensive subjects [20]. Another study, using both a cross-
sectional and longitudinal design demonstrated that a lower degree of
LINE-1 methylation was associated with both prevalent and incident
ischemic heart disease and stroke (the longitudinal analysis, bmedian
vs. ≥ median global DNA-methylation: hazard ratio (HR) = 2.9, 95%CI = 1.3–6.2) [22]. Finally, a cross-sectional study reported an inverse
association between LINE-1 methylation and ischemic stroke in
men (per decrease of 1% in DNA-methylation level, OR = 1.2, 95%
CI = 1.1–3.2) but not in women [21].
3.2.2. Alu methylation and cardiovascular disease
One study of cross-sectional design examined Alumethylation in re-
lation to myocardial infarction and reported a higher degree of methyl-
ation in cases compared to healthy controls [23].
3.2.3. DNA methylation as assessed by LUMA or [3H]-methyl acceptance
and cardiovascular disease
One cross-sectional study reported global DNA hypermethylation to
be associatedwith the presence of coronary artery disease (CAD)within
chronic kidney disease patientswhounderwent hemodialysis [24]. Sim-
ilarly, a prospective study showed that global DNA hypermethylation
was associatedwith increased risk of CVD-mortality (bmedian vs. ≥me-
dian global DNA-methylation, HR = 13.9, 95% CI = 1.8–10.3) [25].
3.3. Gene speciﬁc DNA methylation and cardiovascular disease
DNAmethylation, the addition of amethyl group to the 5 position of
cytosine in a dinucleotide CpG site, is an important mechanism in gene
expression regulation [26]. Loss of DNAmethylation promotes gene ex-
pression [27], however, the association of DNA methylation with gene
expression depends on where within the gene sequence the methyla-
tion occurs. DNA methylation in the promoter region of the gene
Table 2
Speciﬁc gene methylation and cardiovascular disease: gene and genome-wide approaches.
Author CVD outcome Tissue type Population Methylation sites/method Main Finding
Candidate gene approach
Afzali M. et al.
(2013) [31]
CVD (n = 50) PBL M and F,
n = 100
NPC1 promoter/nested methylation
speciﬁc polymerase
The frequency of semi-methylated NPC1
promoter (methylated/un-methylated) is
higher in a CVD patient than in controls
(OR = 6.521, 95% CIs, 2.211–19.215).
The prevalence of methylated allele was
elevated in CVD patients than healthy subjects
(OR = 2.011, 95% CIs, 1.116–3.594)
Baccarelli, A.
et al. (2015)
[45]
CVD (n = 10) Platelet M and F,
n = 27
Mitochondrial genes (cytochrome c
oxidase (MT-CO1, MT-CO2, MT-CO3),
tRNA leucine (MT-TL1), ATP synthase
(MT-ATP6 and MT-ATP8) and NADH
dehydrogenase (MT-MD5)/bisulphite
sequencing
Mean DNA methylation of MT-CO1, MT-CO2,
MT-CO2 MT-TL1 were higher in CVD cases than
in non-CVD subjects (p b 0.001). No differences
were observed in DNA methylation at MT-ATP6,
MT-ATP8 or MT-ND5 between CVD cases and
non-CVD patients.
Breitling, L.P.
et al. (2012)
[39]
CVD-mortality
(n = 64)
WB M and F,
n = 1206
F2RL3/6 CpGs/Sequenom
SpectroACQUIRE and MassARRAY
EpiTyper.
No association was observed between F2RL3
CpG_4 methylation levels and CVD-mortality
comparing the 1st quartile with the fourth
(HR = 2.32, 95% CIs: 0.97–5.58). Per 10% less
methylation: HR = 1.30, 95% CIs: 1.04–1.63.
Fiorito G. et al.
(2014) [43]
MI (n = 206) PB M and F,
n = 412
33 genes involved in homocystein
metabolism and one-carbon
metabolism pathway, 575 CpG
sites/HumanMethylation450
BeadChip
3 differentially methylated regions in males
(TCN2 promoter, CBS 5ʹUTR, AMT gene-body)
and 2 in females (PON1 gene-body, CBS 5ʹUTR)
were identiﬁed, each of them characterized by
an increased methylation in MI subjects. Four
clusters of distinct methylation proﬁle were
identiﬁed, which were differently associated
with the risk of MI (high risk vs. low risk
methylation proﬁle groups: OR= 3.49, p=1.87
× 10−4 and OR = 3.94, p= 0.0317 in males and
females respectively).
Friso S. et al.
(2012) [38]
CAD (n = 165) PBMC M and F,
n = 253
F7 gene promoter, 6 CpGs in
SNPs/methyl speciﬁc PCR primers
and bisulphite sequencing
CAD-free subject showed a higher F7
methylation index compared to CAD patients
(32.12 ± 9.80, p= 0.012). Among the 6 CpGs,
the CpG2, 3 and 6 accounted for the largest
difference in methylation.
Gomez-Uriz
A.M. et al.
(2014) [35]
Stroke (n = 12) WB M and F,
n = 12
TNF-α promoter, 19 CpGs/Sequenom
EpiTyper MassARRAY
Lower values of total TNF-α promoter
methylation, using the median value as cut-off
(median 0.918) was associated with higher
odds of having stroke (OR = 9.0, 95% CIs,
1.4–57.1). The binding pattern of H3K4me3 and
H3K9ac in a region of TNF-αwas similar when
comparing non-stroke and stroke conditions.
Guay S.P. et al.
(2012) [32]
CAD (n = 71) PBL M and F,
n = 97
ABCA1 gene promoter, 26
CpGs/bisulﬁte-pyrosequencing
CAD subjects had higher ABCA1 DNAmethylation
levels compared with those without CAD (34.3 ±
8.4 versus 4.2 ± 15.2, p= 0.003)
Guay S.P. et al.
(2014) [33]
CAD (n = 88) PBL M, n = 88 ABCA1 gene, 8
CpGs/bisulﬁte-pyrosequencing
Subjects with a previous history of CAD showed
higher mean ABCA1 DNA methylation levels than
subjects without CAD (38.7 ± 1.2 versus 36.0 ±
1.0, p= 0.04). These results differ by age (older
CAD-subjects had higher methylation levels than
young CAD-subjects and non-CAD subjects).
Guay S.P. et al.
(2014) [33]
CAD (n = 22) WB M and F,
n = 44
ABCG1-CpGC3, LIPC-CpGA2,
PLTP-CpGC/bisulﬁte-pyrosequencing
Subjects with a previous history of CAD showed
lower mean LIPC-CpGA2DNA methylation levels
than subjects without CAD (83.8 ± 1.9 versus
85.2 ± 1.9, p= 0.02). No differences were
observed in ABCG1-CpGC3 and PLTP-CpGC DNA
methylation.
Huica I. et al.
(2011) [36]
CVD (n = 37) WB ND, n = 62 Estrogen receptor alpha (ERα) and
tissue inhibitors of metalloproteinases
(TIMP-1) speciﬁc PCR primers and
bisulphite sequencing
ERα and TIMP1 presented a statistically
signiﬁcant frequency of hypermethylation in
CVD cases compared to non-CVD cases
(p b 0.001 for each gene). Hypermethylation of
ERα: OR = 43.1, 95% CIs: 9.8–192.3.
Hypermethylation of TIMP1: OR = 15.3, 95%
CIs: 3.8–61.3
Jiang D. et al.
(2013) [34]
CHD (n = 36) PBL M and F,
n = 72
CF1 region of PLA2G7 gene promoter,
4 CpGs/pyrosequencing
There was a higher promoter DNA methylation
of PLA2G7 gene in the CHD cases than in
non-CHD controls (6.41 ± 2.62 versus 4.98 ±
3.06, p= 0.025).
The stratiﬁed analysis by gender, showed that
the signiﬁcant association was found in females
(p= 0.003) but not in males (p= 0.096).
Receiver operating characteristic curves showed
that LA2G7 methylation could predict the risk of
CHD in females (area under the curve = 0.912,
(continued on next page)
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Table 2 (continued)
Author CVD outcome Tissue type Population Methylation sites/method Main Finding
p= 2.40E-5).
Lakshmi S.V.V.
et al. (2013)
[42]
CAD (n = 94) PB ND, n = 177 BCL2/E1B adenovisur interacting
protein 3 (BNIP3), extracellular
superoxide dismutase (EC-SOD)
and glutathione-S-transferase P1
(GSTP1), methyl speciﬁc PCR primers
and bisulphite sequencing
Hypomethylation of BNIP3 promoter in CAD
cases compared to controls (41.95 ± 26.91% vs.
53.51 ± 42.78%, p= 0.03). EC-SOD promoter
hypermethylation was observed in CAD
compared to controls (62.23 ± 33.36%
vs. 32.35 ± 24.76%, p b 0.0001). GSTP1
promoter hypermethylation was observed in
CAD compared to controls, but was not
signiﬁcant (45.63 ± 22.74% vs. 41.67 ± 25.26%,
p= 0.28)
Lu C.X. et al.
(2013) [2]
ACS (n = 89) CD4+CD25+
T-cells
M and F,
n = 124
FOXP3 gene, 2 CpGs/pyrosequencing Demethylation of DNA at FOXP3 gene in ACS
subjects was signiﬁcantly lower than in
non-ACS subjects (p b 0.0001). Analysis
of operating characteristic curve showed an
area under the curve of 0.916 (p b 0.001),
supporting the notion that FOXP3
demethylation can distinguish ACS subjects
from non-ACS subjects.
Peng P. et al.
(2014) [85]
CHD (n = 85) PBL M and F,
n = 139
ABCG1, GALNT2 and HMGCR gene
promoter/bisulphite-speciﬁc PCR
Promoter hypomethylation of the ABCG1
gene was associated with the risk of CHD
(OR = 19.966, 95% CI: 7.319–54.468).
Methylation status of the GALNT2 gene
promoter was associated with the risk of CHD
(OR = 2.978, 95% CI: 1.335–6.649). There was
no association between methylation status of
the HMGCR gene promoter and the risk of CHD
(OR = 2.978, 95% CI: 1.335–6.649).
Sharma, P. et al.
(2008) [24]
CAD (n = 137) PBL M and F,
n = 287
ApoE, 25CpGs/bisulphite sequencing No signiﬁcant difference in methylation
patterns between CAD and non-CAD subjects.
Talens R.P. et al.
(2011) [29]
MI (n = 122) PBL M and F,
n = 248
IL10, LEP, ABCA1, IGF2, INS and
GNASA, 49 CpG sites/Sequenom
EpiTyper MassARRAY
Overall, DNA methylation was modestly higher
in MI cases at GNASAS compared with the
control group (p= 0.03). No differences in DNA
methylation were observed at the other loci. Sex
differences were observed for INS (p-interaction
= 0.014) and GNASAS (p-interaction = 0.031).
In women, DNA methylation at INS (p= 0.002)
and GNASAS (p= 0.009) were higher in MI
cases compared to control. In men, no
differences in DNA methylation were observed.
Overall, hypermethylation at one locus (INS or
GNASAS) and at both loci (INS and GNASAS)
was associated with OR = 1.7 (95% CI:
2.7–27.9) and 2.8 (95% CI = 1.4–5.9)
respectively. In men, no associations were
observed.
Wei L.K. et al.
(2015) [44]
Ischemic stroke
(n = 297)
WB M and F,
n = 407
MTHFR, CpG A and
B/bisulphite-speciﬁc PCR
CpG A methylation levels were associated with
a higher risk for ischemic stroke (OR = 4.73,
95% CI: 2.56–8.75). CpG B methylation levels
were not associated with ischemic stroke
(OR = 0.90, 95% CI: 0.56–1.45).
Xu L. et al.
(2014) [30]
CHD (n = 36) PB M and F,
n = 72
GCK gene-body, 4
CpGs/bisulﬁte-pyrosequencing
CHD cases had a signiﬁcantly lower methylation
level (49.77 ± 6.43%) compared with controls
(54.47 ± 7.65%, p= 0.018). Similar trends were
observed in three CpGs (CpG2, 3 and 4; p for all
b0.05).
Xu L. et al.
(2015) [37]
CHD (n = 784) PB M and F,
n = 1530
4 CpGs of the vascular-related genes
(VEGFA, CST3, AGTR1,
ACE)/Sequenom EpiTyper
MassARRAY
None of the four CpG-SNPs in the vascular
related genes was associated with the risk of
CHD.
Zhang Y. et al.
(2014) [40]
CVD-mortality
(n = 151)
WB M and F,
n = 3572
F2RL3, 4CpG [2 to 5]/Sequenom
EpiTyper MassARRAY
Lower methylation was associated with
increased risk of CVD mortality (comparing the
lowest vs. highest quartile of F2RL3 CpG_4
methylation, HR = 2.94, 95% CIs: 2.45–4.68).
Similar results were observed for other CpGs.
Per 10% less methylation: HR = 1.38, 95% CIs:
1.14–1.66.
Zhuang J. et al.
(2012) [41]
CAD (n = 95) PBL M and F,
n = 205
BAX, BCL-2, TIMP3, p14ARF, p15INK4b
and p16INK4a,seven CpGs at
p15INK4b/MethyLight
p15INK4b was associated with the presence of
CAD (OR = 2.55, 95% CIs, 1.26–5.01). No
association was observed between p16INK4a and
CAD (OR = 1.14, 95% CIs, 0.59–2.36). CpGs
+314 and +332 at p15INK4b site, were
signiﬁcantly increased in CAD patients
compared with controls. No difference was
observed for CpGs +269, +272, +280, +303
and +321
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Table 2 (continued)
Author CVD outcome Tissue type Population Methylation sites/method Main Finding
Genome-wide approaches
Gomez-Uriz
A.M. et al.
(2015) [46]
Ischemic stroke
(Discovery study:
n = 12.
Replication study:
n = 60
PBL M and F,
Discovery study:
n = 24.
Replication
study: n = 115
27,578 CpG sites, 14,495
genes/Illumina human methylation
27 Beads and MassARRAY EpiTyper
80 CpG sites differentially methylated in
patients who suffered an ischemic stroke
compared to those who did not (p b 0.05). 59
CpG sites presented an interaction between
stroke and obesity. Among 21 CpG sites and 15
genes selected as candidates:
• CpG sites 19 and 20 of the gene Wilm's tumor
1 (WT1) showed higher methylation levels in
stroke patients compared to non-stroke sub-
jects (p b 0.05). These results were not repli-
cated in the validation study.
• The promoter region of peptidase M20 do-
main containing 1 (PM20D1) gene was sig-
niﬁcantly hypermethylated in stroke patients
(p b 0.05). Differences in this region were
signiﬁcant at the CpG sites
1_2_10_11_12_13_14_16_17_18_22. These
results were not replicated in the validation
study.
• CpGs 8_9 of KQT-like subfamily, member 1
(KCNQ1) explained 31 and 33% respectively
of the variability for the case stroke in the
validation study.
Sharma P. et al.
(2014) [47]
CAD (Discovery study:
n = 18.
Replication study:
n = 48)
WB M, Discovery
study: n = 132.
Replication
study: n = 96
Bisulphite sequencing by 454
platform
19 differentially methylated regions were
signiﬁcantly hypermethylated in CAD subjects
compared to controls. In the validation study:
out of the 12 differentially methylated regions
selected, 6 CpG sites in 4 regions falling within
three differentially methylated regions had
signiﬁcantly higher methylation in CAD
patients: of the 6 sites, 3 were in the intronic
region of STRADA gene (Homo sapiens
STE20-related kinase adaptor alpha) ﬂanking
CCDC47 and LID2, 2 were in the ﬁrst exon of
C1QL4 gene ﬂanking TROAP and FLJI3236 while
the other was in the intronic region of
HSP90B3P gene ﬂanking CD27 and TGFBR3
Guay S.P. et al.
(2015) [48]
CAD (Discovery study:
n = 6.
Replication study:
n = 45)
WB M, Discovery
study: n = 12.
Replication
Study: n = 161
27,578 CpG sites, bisulphite
sequencing by 454 platform
There were 1765 CpG dinucleotides with
potential DNA methylation differences between
CAD and non-CAD men (P b 0.05). Among 1765
CpGs, 369 CpG dinucleotides were considered as
the most promising differentially methylated
loci. The gene ontology analysis revealed a
signiﬁcant enrichment of genes with epigenetic
changes in biological pathways relevant to CVD
development, such as cellular homeostasis,
proliferation of connective tissue cells,
angiogenesis and cardiovascular system. New
candidate genes emerged: COL14A1
(hypomethylation) and MMP9
(hypermethylation) were associated with CAD
(however, the ﬁndings were not replicated in
the validation study).
ABCA1, ATP-binding cassette sub-family A; ACS, acute coronary syndrome; CAD, coronary artery disease; CHD, coronary heart disease; CI, conﬁdence interval; CVD, cardiovascular disease;
EC-SOD, extracellular superoxide dismutase; ERα, estrogen receptor alpha; F, female; GSTP1, glutathione-S-transferase P1; HR, hazard ratio; M, male; MI, myocardial infarction; MTHFR,
methylenetetrahydrofolate reductase; MTHFR,methylnetetrahydrofolate reductase; NCP1, Niemann-Pick disease type 1; Niemann-pick type C1; NPC1; PB, peripheral blood; PBL, periph-
eral blood leucocyte; PBMC, peripheral blood mononuclear cells; TIMP-1, tissue inhibitors of metalloproteinase; WB, whole blood.
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body promotes the expression of the gene [28]. This can be evaluated
using candidate gene studies and genome-wide approaches:
3.3.1. Candidate gene studies
There were 21 studies (18 cross-sectional studies and 3 prospective
studies) that examined methylation sites in, or near, known candidate
genes for CVD susceptibility in relation to CVDoutcomes (Supplementa-
ry Table S2). Most of the studies used a hypothesis-driven approach,
whereas in others, the choice of genes was based on prior analysis of
gene expression differences in the same subjects. The candidate gene
methylation studies examined a range of genes involved in fetal growth[29], glucose [30] and lipid metabolism [31–34], inﬂammation [34,35],
vascular reactivity [36,37], coagulation [38–40], atherosclerosis [34,36,
41], obesity, oxidative stress [35,42] and in the homocysteine and folate
metabolic pathways [43,44] (Table 2). Adjustment for established CVD
risk factors were done in 13 studies (Supplementary Table S2). DNA
methylation assessment was only done in the promoter region of the
gene in 18 studies. One study assessed DNA methylation in the body
of gene [30] and one study assessed DNA methylation in both sites
[43] (Table 2).
Overall, these studies showed that compared to subjects without
CVD, subjects with an established CVD have higher methylation levels
of Niemann–Pick disease type 1 (NCP1), ATP-binding cassette sub-
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eral blood leucocyte, extracellular superoxide dismutase (EC-SOD), es-
trogen receptor alpha (ERα), tissue inhibitors of metalloproteinase
(TIMP-1), methylenetetrahydrofolate reductase (MTHFR) in whole
blood, F7 in peripheral blood mononuclear cells, glutathione-S-
transferase P1 (GSTP1) in PB, FOXP3 in CD4+CD25+ T-cells and of
genes involved in homocysteine metabolism and one-carbon metabo-
lism pathway (TCN2, CBS 5ʹUTR and AMT in males and PON1 and CBS
5ʹUTR in females) in peripheral blood, and lower methylation levels of
ABCG1 in peripheral blood leucocytes, adenovirus interacting protein 3
(BNIP3) in peripheral blood, and of F2RL3, tumor necrosis alpha (TNF-
α), LIPC, GCK, F2RL3 and BCL2/E1B in whole blood (Table 2 and Supple-
mentary Table S3). Furthermore, one study that analyzed platelet mito-
chondrial DNA methylation levels of genes associated with ATP
synthesis and of tRNA leucine gene 1 (MT-TL1) showed protein-
encoding cytochrome c oxidase genes (MT-CO1, MT-CO2 and MT-CO3)
andMT-TL1 to be hypermethylated in CVD cases compared to healthy
controls [45]. The most consistently reported epigenetic association
was that of methylation at the F2RL3 in whole blood with the risk of
CVDmortality whichwas reported in 2 prospective studies, one that in-
cluded CVD-free participants and the other that included participants
with established CVD [39,40]. Both studies showed that hypomethyla-
tion at F2RL3 was associated with increased risk of CVD-mortality (per
10% less methylation, Breitling et al.: HR = 1.30, 95% CI, 1.04–1.63;
Zhang et al.: HR = 1.38, 95% CI, 1.14–1.66). Three studies showed sex-
differences in the association between gene-speciﬁc DNA methylation
and CVD [29,34,43]. Collectively, these studies suggest that altered epi-
genetic regulation of a number of metabolic genes (Supplementary
Table S3) could be involved in cardiovascular disease etiopathogenesis.
3.3.2. Genome-wide analysis for cardiovascular disease
Due to the advent of genome-wide arrays for quantifying site-
speciﬁc DNAmethylation, several studies have investigated differential-
ly methylated regions in the genome in a hypothesis-free approach.
Three studies looked for CVD-associated differentially methylated sites
in peripheral blood cells [46–48]. All three studies used a replication
study to validate their ﬁndings. Collectively, up to 1675 CpG dinucleo-
tides were identiﬁed with potential DNA methylation related to risk of
CVD. The identiﬁed genes were enriched for genes (known from
genome-wide association studies) with epigenetic changes in biological
pathways relevant to CVD-development, such as cellular homeostasis,
proliferation of connective tissue cells, angiogenesis and cardiovascular
system (Table 2). Among them, 4 loci were validated (STRADA, C1QL4,
HSP90B3P and KCNQ1) (Table 2 and Supplementary Table S3). Also,
new candidate genes emerged such as COL14A1 (hypomethylation)
and MMP9 (hypermethylation) which were reported to be associated
with CAD [48].
3.4. Histone modiﬁcations and cardiovascular disease
Two studies examined the association between histone modiﬁca-
tions and CVD (Supplementary Table S4) [35,49]. One study showed
that the levels of acetylated histoneH3 in the peripheral bloodmononu-
clear cells of acute ischemic stroke patients were lower than normal
controls [49] whereas the other study reported no difference in the
binding pattern of H3K4me3 and H3K9ac in a region of TNF-α when
comparing non-stroke with stroke patients [35].
4. Discussion
The presentwork is the ﬁrst to systematically review the current ev-
idence for the role of epigeneticmarks in CVD. Ourﬁndings indicate that
global DNA methylation might inﬂuence CVD risk and this could occur
beyond the traditional cardiovascular risk factors. Furthermore, DNA
methylation at 34 genes seems to be associated with the risk of CVDthrough mechanisms including inﬂammation, hyperlipidemia and oxi-
dative stress.4.1. Global DNA methylation
The results of the present review support global DNA methylation
measured in LINE-1 repeats to be inversely associated with the risk of
CVD, independent of established cardiovascular risk factors. LINE-1
methylation was used in several studies as a marker of global DNA
methylation. Given that LINE-1 is themost common repetitive sequence
in the human genome and one third of DNAmethylation in the genome
occurs in these elements, the use of LINE-1 methylation as a marker of
global DNA methylation seems justiﬁed [17,50]. Moreover, LINE-1
methylation correlates with other methods including genomic 5-
methyl cytosine content and luminometric methylation assay (LUMA)
[18,51].
However, little is known about the biological function of LINE-1. The
majority of LINE-1 copies are found to be inactive, however,multiple so-
matic cells express it which triggers senescence [52]. LINE-1 hypome-
thylation in the peripheral blood cells has been associated with
diabetes, obesity, lower levels of HDL-cholesterol, elevated levels of
total cholesterol and inﬂammation and a higher risk of metabolic status
worsening [20,53–57]. Also, higher plasma glucose levels and blood
pressure, along with greater risk for metabolic syndrome [58] have
been reported to inversely associate with LINE-1 methylation levels in
other tissues, such as visceral fat. All these suggest that LINE-1 hypome-
thylation is associated with an unfavorable cardiovascular risk proﬁle
[57,59]. Furthermore, it has been previously shown that suppression
of LINE-1 expression improves the outcomes after MI by ameliorating
post-ischemic functional recovery and decreasing infarct size through
Akt/PKB signaling [60].
In contrast to studies that used LINE-1 as an index of global DNA
methylation, other studies reported a higher degree of global DNA-
methylation to be associated with CVD. These studies assessed global
DNA methylation in other repetitive elements such as Alu repeats,
and/or used other methods to asses DNA methylation rather than
bisulphate pyrosequencing. LINE-1 and Alu repeats represent distinct
measures of dispersed DNAmethylation, andmight have different func-
tions [61]. The quantitative assessment of DNA methylation at ALU is
about one-third to one-fourth ofmethylation at LINE-1,whichmay sug-
gest that epigenetic changes at LINE-1 and ALUmightmeasure different
traits [61]. Moreover, the assay used and the source of DNA are impor-
tant determinants in the interpretation of global DNA methylation pat-
terns. For instance, global DNAmethylation assessed by LUMAmodestly
correlateswith LINE-1methylation [62]. Furthermore, DNAmethylation
occurs throughout the genome in a sequence-context-dependent fash-
ion, and the extent to which regional sequence contextmight affect dif-
ferent measures of DNA methylation is unknown. Finally, similar
opposing effects between LINE-1 and Alu methylation are observed
with cardio-metabolic risk factors and other diseases, such as cancer
and Alzheimer [57,63–65].
The contradicting observationswith differentmarkers of global DNA
methylation may raise a question on how functionally such a measure
could beuseful. It should be noted thatmethylation has a different effect
depending on its position towards coding genes. Hypermethylation of
the promoter CpG island is usually associated with gene transcriptional
silencing and their hypomethylation of CpG islands is generally associ-
atedwith increased gene expression [28]. In contrast, hypermethylation
at the gene-body is associated with increased gene expression [66].
Therefore, global DNA methylation provides an oversimpliﬁed assess-
ment of epigenetic dysregulation, as it neither quantitatively nor quali-
tatively acknowledges the co-existence of hypo- and hypermethylation
within a gene or distinct geneswithin the same cell. Thus, further efforts
are needed to dissect themolecular phenotype of these alterations, their
link to disease processes and methodologies capable of distinguishing
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these elements.
4.2. Epigenetic wide-association studies and candidate gene approach
Our study denotes 34 genes to be differentially methylated accord-
ing to the presence of CVD. Among the 34 sites reported to be differen-
tially methylated, the DNA methylation at F2RL3 and the risk of CVD
mortality was the most consistently epigenetic association found in
this review. Furthermore, 5 loci, including ABCA1, KCNQ1 and C1QL4
were validated. It is hypothesized that the epigenome regulates gene
expression, cardiovascular risk factors and eventually risk of CVD [42].
Of note, these gene/genes regions are known to affect biological pro-
cesses related to CVD, such as homeostasis, endothelial dysfunction, in-
ﬂammation and oxidative stress. Also, some of these genes are
implicated in lipid metabolisms. For example, ABCA1 gene is critical in
promoting the efﬂux of cellular cholesterol and phospholipids onto
small pre-beta 1 high-density lipoprotein cholesterol (HDL-C) practices
and in converting them to larger alpha migrating HDL-C practices [67].
ABCA1 gene variants are associated with the levels of HDL-C and the
risk of developing coronary heart disease [68]. Also, KCNQ1 gene en-
codes for a voltage-gatedpotassium channel required for the repolariza-
tion phase of cardiac action potential and mutations at this gene are an
uncommon cause of atrial ﬁbrillation [69]. Also, methylation of some of
these genes has been associated with cardio-metabolic risk factors,
e.g., epigenetic changes at the ABCA1 gene promoter region contributes
to the inter-individual variability in plasma HDL-cholesterol and meth-
ylation at F7 and TNF-α promoter regions has been associatedwith plas-
ma factor VII concentrations and body weight respectively [32,35,38].
The association between DNA methylation at F3RL3 and CVD mortality
was beyond the traditional risk factors for CVD. Methylation at F2RL3
has been associated with smoking, a well-established risk factor for
CVD [70]. Also, the gene product of F2RL3 is implicated in platelet acti-
vation, intimal hyperplasia and inﬂammation [71]. It could be expected
that the identiﬁed regions constitute only a small fraction of the epige-
nome related to CVD. Further research is therefore needed to identify
such regions and establish a cause-and-effect relation between methyl-
ation of these loci anddevelopment of CVD and elucidate the underlying
mechanisms, including eventual possibilities of developing epigenetic
risk assessments for CVD as well as prevention strategies.
4.3. Histone modiﬁcations
This review underscores a number of gaps in the literature
concerning CVD and histone modiﬁcations, an important epigenetic
mechanism that can be involved in CVD. Modiﬁcations in histone H3
in smooth muscle cells in atherosclerotic regions compared to normal
arteries have been uncovered [72,73]. Also, recent studies have shown
that histone modiﬁcations may have an impact in adipogenesis, energy
homeostasis, inﬂammation and diabetes [74–77].
4.4. Study design, causality, bias and confounding
In the current investigation we found that epigenetic markers were
associated with CVD; however, identifying causality is difﬁcult due to
the unstable nature of the epigenome and the cross-sectional design
of the majority of studies included. In the current review, except for
ﬁve studies, the epigenetic marks and CVD were assessed at the
same time point, making it difﬁcult to conclude whether speciﬁc epige-
netic marks are a cause or consequence of CVD. Longitudinal studies
with repeated measurements of DNA methylation before disease
development and after it may help provide stronger evidence towards
causation. Moreover, statistical approaches such as Mendelian Ran-
domization may provide another opportunity to study the direction
of causation from cross-sectional data, but this approach requires a
large sample size. Moreover, the majority of the studies in our reviewlack the adjustment for basic covariates such as sex and age and also
for the established cardiovascular risk factors. All the included studies,
except one, were classiﬁed as low quality, mainly due to the lack of
proper adjustment. Unlike genetic association studies which are resis-
tant to confounding, controlling for different confounders and media-
tors is of importance in epigenetic analysis.
4.5. Strengths and limitations
The strengths and limitations of the ﬁndings from this study merit
careful consideration. The present analysis, involving data from nearly
13,000 individuals, is theﬁrst systematic review on the subject that crit-
ically appraised the literature following an a priori designed protocol
with clearly deﬁned inclusion and exclusion criteria. However, as men-
tioned above, on themajority of studies included are cross-sectional as-
sessments, making it difﬁcult to conclude whether speciﬁc epigenetic
marks are a cause or consequence of CVD. Also, the included studies
were limited in sample size and while individual studies attempted to
adjust for established cardiovascular risk factors, the levels of adjust-
ment was inconsistent across the studies. Although every effort has
been made to undertake a comprehensive search of the literature, we
cannot exclude the possibility of publication bias from underreporting
negative ﬁndings. Furthermore, a meaningful quantitative pooling of
the existing data was unfeasible due to heterogeneity in the input pa-
rameters, assumptions and the study design.
4.6. Perspective and conclusion
The study of epigenetic markers is emerging as one of the most
promising molecular strategies for risk stratiﬁcation for complex dis-
ease, including CVD, and when implemented will have a sizable public
health impact. Peripheral blood is easy to access and reﬂects multiple
metabolic and inﬂammatory pathways [78,79]. Therefore, methylation
proﬁling in peripheral blood to identify CVD-relatedmethylated regions
is of great interest since theywould allow clinicians to identify high-risk
individuals whomay beneﬁt from preventive and therapeutic interven-
tions, promising high potential clinical utility [80]. Thus, large-scale epi-
genetic investigations are needed to characterize the identiﬁed site-
speciﬁc DNA methylation in this review and other methylated sites
that will predict CVD. Also, as epigenetic DNA modiﬁcations are poten-
tially reversible and may be inﬂuenced by nutritional–environmental
factors and through gene–environment interactions, future therapies
targeting the epigenome can be a novel preventive strategy and treat-
ment for CVD. For example, some studies show that supplementation
with methyl donors such as folate, choline and vitamin B12 may inﬂu-
ence DNA methylation and may have a beneﬁcial effect on CVD risk,
but results are still inconsistent [81–84]. Also, epigenetic drugs have
been shown to successfully reverse several epigenetic marks and dis-
ease symptoms and have been approved by FDA for use in cancer [9].
Therefore, in the background of the high burden of CVD despite great
advances in its prevention and treatment, transfer of these novel thera-
peutic avenues on the ﬁeld of CVD should become a research priority in
the future. However, epigenetic therapeutics should aim to modify var-
ious epigenetic elements in a complex and intricate cross-talk without
disturbing further pathways. Also, to constitute potential therapeutic
and preventive strategies in epigenetic medicine, in addition to folate,
vitamin B6 and B12, a better understanding of other C1-metabolites
(e.g., S-adenosylmethionine and S-adenosylhomocysteine) in CVD is
of great interest in the forthcoming years. Also, because small differ-
ences in methylation values determine a diseased or disease-free
state, the need for harmonizing an appropriate method for quantitative
DNA methylation detection is critical. Only the application of sophisti-
cated methods for analysis of DNA methylation, which may be
standardized across different laboratories, will provide reliable data
that may conﬁrm the importance of epigenetics in CVD. Furthermore,
future studies should explore further areas of epigenetic regulatory
182 T. Muka et al. / International Journal of Cardiology 212 (2016) 174–183mechanisms beyondDNAmethylation, including histonemodiﬁcations,
which remain very poorly characterized in the context of CVD.
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